Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab′) 2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels

Edward A. Panacek, John C. Marshall, Timothy E. Albertson, David H. Johnson, Steven Johnson, Rodger David MacArthur, Mark Miller, William T. Barchuk, Steven Fischkoff, Martin Kaul, Leah Teoh, Lori Van Meter, Lothar Daum, Stanley Lemeshow, Gregory Hicklin, Christopher Doig

Research output: Contribution to journalArticle

263 Scopus citations

Fingerprint Dive into the research topics of 'Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab′) <sub>2</sub> fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels'. Together they form a unique fingerprint.

Medicine & Life Sciences